LAM International

AI Therapeutics (formerly LAM International and LAM Therapeutics) is a clinical-stage biopharmaceutical company that utilizes an artificial intelligence-driven platform to accelerate the discovery and development of new treatments for rare diseases and cancer. Founded by Dr. Jonathan Rothberg as part of the 4Catalyzer incubator, the company leverages its 'Guardian Angel' platform to match drugs with specific patient populations. Its lead candidates include LAM-002 (apilimod), a PIKfyve inhibitor being evaluated for B-cell malignancies and neurological disorders, and LAM-001, an inhaled formulation of rapamycin for the treatment of lymphangioleiomyomatosis (LAM). The company focuses on repurposing and optimizing existing compounds using advanced computational biology and deep learning. By combining high-throughput screening with AI, the company aims to significantly reduce the time and cost of drug development.